Stem Cell Therapy International, Inc. Announces the Distribution of Histostem Products |
 |
 |
| Thursday, 25 June 2009 16:44 |
|
In anticipation of the finalization of the merger between Stem Cell Therapy International, Inc. and Histostem, David Stark, SCTI President and CEO, has been working closely with Histostem management to prepare the supply channels and to network with various retailers to enable AmStem International, Inc. to begin US distribution and immediately bolster the company's cash flow. Details about the manufacturing and shipping of the Stem Cell Facial Cream, for example, have been worked out and are ready for implementation. "The response to our Stem Cell Facial Cream has been extremely positive," informs Mr. Stark, "and because we have a proven market presence in Asia, proprietary supply chain, GMP-approved manufacturing facility, and some very promising study results, we are ready to partner with a major distributor right now." AmStem International is also seeking investigators for a clinical study of the highest caliber, to compare its Stem Cell Facial Cream with others on the market. "Our experience with clinical trials is crucial," claims Mr. Stark. "We will be conducting a scientifically and statistically valid study, IRB-approved, and ethically sound. It will be conducted with GCP standards set by FDA, ICH, and other regulatory agencies. This study will compare our Stem Cell Facial Cream vs. inactive placebo and 3 competing products in a controlled, randomized protocol." He adds, "This is attracting leaders in the field as investigators, and we are confident that our study results will be phenomenal." Stem Cell Therapy International, Inc. continues to work on the necessary steps to finalize the merger, and both sides are working diligently to manage its many details. "We will continue to collaborate closely with Histostem to ensure the greatest benefit for our stockholders and investors," adds Mr. Stark. About Stem Cell Therapy International, Inc. Stem Cell Therapy International, Inc. ( About AmStem International, Inc. AmStem International, Inc. is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Further information about AmStem International, Inc. can be found by contacting David Stark, SCTI President, at the email posted below. About Histostem Corporation, Ltd: Histostem Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and six patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Further information about Histostem Corporation, Ltd. can be found by contacting David Stark, SCTI President, at the email posted below. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
TAMPA, FL-- Stem Cell Therapy International, Inc. (
Free Phone Trade Alerts
